Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) was the recipient of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 2,060,000 shares, a drop of 5.9% from the April 30th total of 2,190,000 shares. Approximately 3.1% of the company’s stock are sold short. Based […]
Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) saw a significant increase in short interest in the month of April. As of April 30th, there was short interest totalling 2,190,000 shares, an increase of 5.3% from the April 15th total of 2,080,000 shares. Based on an average daily trading volume, of 364,900 shares, the days-to-cover ratio […]
Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX – Get Rating) have earned an average recommendation of “Buy” from the seven ratings firms that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers that have covered the stock in the last […]
Compass Therapeutics (NASDAQ:CMPX – Get Rating) and BioAtla (NASDAQ:BCAB – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations. Valuation & Earnings This table compares Compass Therapeutics and BioAtla’s […]
Compass Therapeutics (NASDAQ:CMPX – Get Rating) and BioAtla (NASDAQ:BCAB – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, dividends, risk, institutional ownership and earnings. Institutional and Insider Ownership 54.3% of Compass Therapeutics shares are […]